VAERS 1652308
PFIZER\BIONTECH · COVID19 (COVID19 (PFIZER-BIONTECH)) · Charge EW0173 8/21
- Staat
- NJ
- Alter
- 42,0
- Geschlecht
- F
- Eingang
- 28.08.2021
- Impfdatum
- 12.05.2021
- Beginn
- 12.05.2021
- Tage bis Beginn
- 0,0
- Dosis
- 1
- Route/Site
- - / LA
Symptomtext
Severe arm pain night after shot arm was unable to move/ moderate/mild pain in the upperarm; This is a spontaneous report from a non-contactable consumer, the patient. A 42-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0173 8/21) via an unspecified route of administration in the arm left on 12May2021 at 16:00(at the age of 42-year-old) as a single dose for COVID-19 immunisation. Medical history included celiac disease from unknown date and unknown if ongoing. Concomitant medications included only vitamins/supplements (MANUFACTURER UNKNOWN) from unknown date for unspecified indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12May2021 the patient experienced severe arm pain night after shot, all night long her whole arm was unable to move. This strong pain subsided in about 2 days. Now 2 weeks later, she still have moderate/mild pain in the upper arm. The patient did not receive any treatment for the event. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event severe arm pain night after shot arm was unable to move was recovering. No follow-up attempts are needed. No further information is expected.
Weitere VAERSDATA-Felder
- Praegender Schweregrund
- Pain in extremity
- Hospital-Tage
- -
- Labordaten
- -
- Aktuelle Erkrankungen
- -
- Vorgeschichte
- Medical History/Concurrent Conditions: Celiac disease
- Andere Medikamente
- -
- Allergien
- -
- Vorherige Impfungen
- -